This trial is evaluating whether Cyclophosphamide will improve 1 primary outcome and 2 secondary outcomes in patients with Cancer of Pancreas. Measurement will happen over the course of 4 years.
This trial requires 19 total participants across 2 different treatment groups
This trial involves 2 different treatments. Cyclophosphamide is the primary treatment being studied. Participants will be divided into 2 treatment groups. There is no placebo group. The treatments being tested are not being studied for commercial purposes.
"Patients with cancer of pancreas should be investigated with diagnostic tests to detect any early cancer of pancreas. For early detection, the use of endoscopic ultrasound, biopsy, or fine needle aspiration should be encouraged." - Anonymous Online Contributor
"Chemotherapy is the only possible curative treatment for the majority of the patients with [pancreas cancer](https://www.withpower.com/clinical-trials/pancreas-cancer), but it is possible to cure more patients based only on surgery. The most important of all treatments is cancer-specific counseling and education for patients and their family. There are many kinds of cancer treatments. But for patients with pancreas cancer, it is possible to manage these patients by using the treatments that are based on disease stage before diagnosis, surgery and other treatments." - Anonymous Online Contributor
"Cancer of pancreas can be highly curable or fatal depending on the stage of the disease and the extent of the cancer at the time of cancer diagnosis." - Anonymous Online Contributor
"About 40,000 Americans get [pancreatic cancer](https://www.withpower.com/clinical-trials/pancreatic-cancer) a year. Diabetes appears to increase the risk for malignancy, but it is not associated with any significant increase in risk of other types of cancer." - Anonymous Online Contributor
"Pancreatic cancer accounts for less than 3% of all solid cancers. It is very rare in children. Older individuals are more prone to develop pancreatic cancer. The 5-yr survival is 35%. The most frequent site of cancer in the pancreas is head of pancreas (72%) and then in the body region (16%), followed by distal bile ducts (8%), and then the tail (5%)." - Anonymous Online Contributor
"The cause of [pancreatic cancer](https://www.withpower.com/clinical-trials/pancreatic-cancer) remains unknown. It is thought that cancer can develop in the pancreas due to genetic factors, exposure to cancer-causing toxins or hormones, lifestyle factors, immunological factors and environmental factors." - Anonymous Online Contributor
"We conclude that curative radical surgery is the most efficient therapy for localized tumours but has limited usefulness if the tumour is highly invasive or metastatic. The latter has a dismal prognosis without any treatment. The survival rate, particularly after metastasis has been reported in literature to be high, indicating intensive surgery. There is a need to study the biological and epidemiological mechanisms of the high rate of metastasis in pancreas." - Anonymous Online Contributor
"On average cyclophosphamide treats more patients safely than many conventional cytotoxic agents. Unlike some cytotoxic agents that have a narrow therapeutic index, cyclophosphamide has an extremely low toxicity profile and is often considered a first-line treatment for breast cancers.. Cyclophosphamide is used in treatment of many other hematological malignancies and also in non-malignant disorders such as autoimmune and inflammatory diseases.. The following is a partial list of clinical trial trials in which cyclophosphamide is used in treatment of various disease indications. For cyclophosphamide pharmacology, see Cyclophosphamide." - Anonymous Online Contributor
"For patients with advanced or metastatic pancreatic adenocarcinoma, cyclophosphamide combined with a number of other agents, including mitomycin, ifosfamide, etoposide, doxorubicin and vincristine was found to be effective, but with greater toxicity in a phase IIb trial with intent to replace conventional cyclophosphamide-based regimens (and may not be effective against non-metastatic disease). Results from a recent clinical trial of this study also indicate that for this specific patient population, the conventional CHOP regimen has a very high rate of early and late toxicity." - Anonymous Online Contributor
"A significant number of studies have been conducted in the last 5 years to develop effective ways for detecting and treating diabetes. Current research aims at developing new methods to diagnose, assess, and treat [pancreatic cancer](https://www.withpower.com/clinical-trials/pancreatic-cancer). Diabetes research also aims at developing better methods of detection and treatment. In this context, the European Diabetes Research Programme (EDRP) will be involved in the European project, [EUROCAN] (https://www.eurocanprogram.eu/). The EUROCAN project is focused on the development of new effective tools and techniques for early cancer detection. Such techniques are aimed at improving the diagnostic process of pancreatic cancer by increasing the detection rate of pancreatic tumors." - Anonymous Online Contributor
"Although most patients are managed non-pharmacologically, cyclophosphamide monotherapy (single agent) has been an important chemotherapeutic approach in the treatment of EAC over the past 35 years, as evidenced by our institutional experience with treatment results, response rates, and survival as well as published series. This approach to treatment has proven to be safe and durable with only moderate toxicities. The optimal approach and timing and duration of chemo therapy remains to be determined." - Anonymous Online Contributor
"There is a higher rate of disease recurrence and lower survival for PCa compared to BPCa and the incidence of PCa is [1.0% compared to 0.7% and 0.3% of BPCa] per 100 patient/year. PCa is also more [disease-specific] mortality for both men and women than BPCa. The incidence of PCa in this study [is 8.8/100,000 person-years-1,000] is higher than the reported incidence of PCa in China [3.3/100,000 person-years-1,000] and may not be the same as the incidence reported in many developed countries." - Anonymous Online Contributor